ClinicalTrials.gg
RecruitingNCT06736483DEXPEDUpdated Oct 13, 2026

Intravenous Dexmedetomidine as an Adjuvant to Locoregional Anesthesia in Pediatric Surgery

A Phase 2 interventional study of Dexmedetomidine and Placebo administration in Anesthesia and Pediatric Surgery, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 1 Year to 7 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University Hospital, Montpellier · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 13, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
1 Year to 7 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing dexmedetomidine in Pain — 11 open to participants now, 12 under way, 2 of them phase 3. Dexmedetomidine · Pain.

Planned enrollment
4th of 63
200 · median 70
Started
2025
with 5 others
Phase 2
8 of 64
1 open now
Primary completion
2028-07
later than 10 of 11 live
Registered
53rd of 64
by date

Among the 64 studies testing dexmedetomidine in Pain, this one is the 4th largest by planned enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 8 in phase 2, reaches primary completion later than 10 of the 11 other live ones, and was the 53rd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

11 of the 64 studies testing dexmedetomidine in Pain are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 1 Year to 7 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing dexmedetomidine in Pain, or all of them as a file.
02

Study summary

The main objective of this study is to study the impact of intravenous dexmedetomidine combined with locoregional anesthesia on postoperative pain in children undergoing surgery.

Secondary objectives was to compare beetwen groups : Post-operative pain; opioid consumption; incidence of emergence delirium, post-operative behavioral disorders, length of stay in the PACU, adverse events , parental satisfaction and quality of life.The goal of this clinical trial is to assess intravenous dexmedetomidine to prevent post-operative pain in children undergoing surgery.

This study is prospective and children will be randomized in one of the following arm:

  • Dexmedetomidine (experimental treatment)
  • Placebo The experimental treatment or placebo will be administrated at one time point at the time of incision.

Participants and their legal representative will have to respond to questionnaires at several time points following the surgery: Day 1, Week 1, Month 3 and Month 6.

Read the detailed description

Postoperative pain, which can develop into chronic pain in children, can have a significant impact on the quality of life of the child and their parents. Management of acute postoperative pain is crucial to prevent chronic pain, and perioperative opioid sparing aims to reduce opioid side effects. The emergence of postoperative delirium (ED) is also a concern, as it can cause intense agitation and diagnostic difficulties. Dexmedetomidine, in addition to its sedative and analgesic effects, has been shown to prolong the duration and effectiveness of regional anesthesia (LAR), thereby reducing the need for opioids and attenuating the severity of postoperative delirium. Its use in these settings could improve pain management and reduce complications associated with pediatric surgery, thus offering a promising therapeutic option.

03

Conditions studied

  • Anesthesia
  • Pediatric Surgery

Keywords

  • loco-regional anesthesia
  • Pain
  • Emergence delirium
04

Who can participate

Ages eligible
1 Year to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1 to 7 years old male or female
  • To be hospitalized for scheduled urovisceral orchidopexy or peritoneovaginal canal surgery (inguinal hernia or hydrocele cure) on an outpatient basis
  • Local-regional anesthesia via Transversus Abdominis Plane (TAP) block and/or pudendal block
  • National health insurance coverage
  • Have obtained signed from holders of parental authority
  • American Society of Anesthesiology (ASA) score : 1-2
  • French read, written and spoken by legal representatives

Exclusion criteria

Exclusion Criteria:

  • Patient under 1 or over 8 years old
  • Patients with allergies to local anesthetics
  • Patient with a to locoregional anesthesia: coagulation disorder or infection (fasciocutaneous) in the puncture zone
  • Patients with a contraindication to dexmedetomidine ( to the active ingredient or one of the , advanced heart block (level 2 or 3), uncontrolled hypotension, acute cerebrovascular pathologies)
  • Patients with delayed psychological development, cognitive or behavioral disorders, or severe neurological pathology.
  • Patients and/or parents who refused to participate in the study
  • Proven allergy or contraindication to dexmedetomidine or nalbuphine
  • Previous study participants
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine

    Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.

    Drug: Dexmedetomidine · Other: Face Legs Activity Cry Consolability scale · Other: Post-Hospitalization Behavior Questionnaire · Other: Postoperative pain measure · Other: Post-operative quality of life questionnaire

  • Placebo comparator
    Placebo

    Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision

    Drug: Placebo administration · Other: Face Legs Activity Cry Consolability scale · Other: Post-Hospitalization Behavior Questionnaire · Other: Postoperative pain measure · Other: Post-operative quality of life questionnaire

Interventions

  • Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.

  • DrugPlacebo administration

    Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision

  • OtherFace Legs Activity Cry Consolability scale

    The pain will be assessed on admission and every 15 minutes until discharge from the PACU

  • OtherPost-Hospitalization Behavior Questionnaire

    The Post-Hospitalization Behavior Questionnaire will be completed at day 1 and at day 7

  • OtherPostoperative pain measure

    The Postoperative pain measure will be completed by parents at day 1, day 7, 3 months and 6 months

  • OtherPost-operative quality of life questionnaire

    The Post-operative quality of life questionnaire pedQL will be completed at 3 and 6 months

06

What researchers measure

Primary outcomes

  1. Rescue analgesic

    Rescue analgesic (Nalbuphine, Nubain®) administration in the PACU between the 2 arms.

    Time frame: From the end of surgery to hospital discharge (up to 7 days)

Secondary outcomes

  1. Postoperative pain

    Assessment of postoperative pain using the Face Legs Activity Cry Consolability (FLACC) scale: on admission and every 15 minutes until discharge from the PACU, then before returning home.

    Time frame: From the end of surgery to hospital discharge (up to 2 days)

  2. Intraoperative morphine consumption

    Time frame: From anesthesia induction to the end of surgery (up to 24 hours)

  3. Emergency analgesics

    Dose in milligrams of emergency analgesics in the PACU

    Time frame: From the end of surgery to hospital discharge (up to 24 hours)

  4. Adverse events

    Incidence of opioid-related side effects (respiratory complications - postoperative nausea and vomiting)

    Time frame: From the end of surgery up to 7 postoperative days

  5. Length of hospital stay

    Length of hospital stay in hours from admission to discharge

    Time frame: From the start of hospitalization to hospital discharge (up to 7 days)

  6. Ped-PADSS score

    The Post-Anesthetic Discharge Scoring System aimed to assess the possibility of discharge. The minimum is 0 and the maximum 10. A score of 9 or 10 authorizes hospital discharge.

    Time frame: From the end of surgery to hospital discharge (up to 2 days)

  7. Pediatric Anesthesia Emergence Delirium

    Incidence of emergence of delirium in the PACU according to the Pediatric Anesthesia Emergence Delirium (PAED) scale. Score from 0 to 20, a score \> 9 indicates an emergence delirium

    Time frame: From the end of surgery to hospital discharge (up to 24 hours)

  8. Post-Hospitalization Behavior Questionnaire

    Post-Hospitalization Behavior Questionnaire at day 1 and day 7. This questionnaire is composed of 27 items rated from 1 to 5, minimum score : 27, maximum score: 135. A score above 68 is associated with an increase in postoperative behavioral problems.

    Time frame: From the end of surgery up to 6 postoperative months

  9. Postoperative Pain Measure For Parents

    Postoperative Pain Measure For Parents at 7 days, 3 and 6 months. Score: from 0 to 10 with 10 items. A score above 6 indicates significant pain.

    Time frame: From the end of surgery up to 6 postoperative months

  10. Post-operative quality of life questionnaire

    Post-operative quality of life questionnaire pedsQL at 3 and 6 months. The 23 questions cover 4 different domains: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items) and academic functioning (5 items). The parent questionnaire assesses parents' perceptions of their child's health-related quality of life.

    Time frame: From the end of surgery up to 6 postoperative months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2028, 41 months after the start.

Of 125 non-industry phase 2 interventional studies under Pain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 41 months is above that.

Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 8 and three quarters within 40.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2027 → Jul 2028, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 16, 2024
StartActual
Feb 3, 2025
Primary completionEst.
Jul 3, 2028was Jul 2027
CompletionEst.
Jul 3, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • UH of Montpellier · Montpellier, France
Show 1 removed
  • UH of Montpellier · Montpellier, France
Oct 13, 2026
Primary completion
Jul 3, 2027→Jul 3, 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added, 1 site removed
    Show site
    • UH of Montpellier · Montpellier, France
    Show 1 removed
    • UH of Montpellier · Montpellier, France
    Primary completion Jul 3, 2027→Jul 3, 2028
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06736483
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Feb 3, 2025
Primary completion
Jul 3, 2028 (estimated)
Completion
Jul 3, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Julien PICO, MD
Contact
j-pico@chu-montpellier.fr
+33 7 88 01 44 14

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion